Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials

被引：0
|
作者：
Neyns, Bart
Weber, Jeffrey S.
Lebbe, Celeste
Maio, Michele
Harmankaya, Kaan
Hamid, Omid
O'Day, Steven
Chin, Kevin M.
McDowell, Diane Opatt
Cykowski, Lori
McHenry, Brent
Wolchok, Jedd D.
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Comprehens Melanoma Res Ctr, H Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Hop St Louis, Paris, France
[4] Ist Toscano Tumori, Univ Hosp Siena, Siena, Italy
[5] Med Univ Vienna, Div Gen Dermatol, Dept Dermatol, Vienna, Austria
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIVE-YEAR SURVIVAL RATES FOR PATIENTS (PTS) WITH METASTATIC MELANOMA (MM) TREATED WITH IPILIMUMAB (IPI) IN PHASE II TRIALS
    Lebbe, Celeste
    Weber, Jeff
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Chin, Kevin
    McDowell, Diane
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 309 - 309
  • [2] Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
    Ascierto, P. A.
    Del Vecchio, M.
    Robert, C.
    Mackiewicz, A.
    Chiarion-Sileni, V.
    Arance Fernandez, A. M.
    Schmidt, H.
    Lebbe, C.
    Bastholt, L.
    Hamid, O.
    Rutkowski, P.
    McNeil, C.
    Garbe, C.
    Loquai, C.
    Dreno, B.
    Thomas, L.
    Grob, J. J.
    Hennicken, D.
    Qureshi, A.
    Maio, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] FIVE-YEAR SURVIVAL RATES FOR PATIENTS (PTS) WITH METASTATIC MELANOMA (MM) TREATED WITH IPILIMUMAB (IPI) IN PHASE II TRIALS
    Lebbe, C.
    Weber, J. S.
    Maio, M.
    Neyns, B.
    Harmankaya, K.
    Chin, K.
    McDowell, D. Opatt
    Cykowski, L.
    McHenry, M. B.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 363 - 364
  • [4] Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials
    Maio, M.
    Lebbe, C.
    Sileni, V. Chiarion
    Siegel, J.
    Hoos, A.
    Humphrey, R.
    O'Day, S.
    Wolchok, J.
    Weber, J.
    Harmankaya, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 578 - 578
  • [5] Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
    O'Day, S.
    Weber, J.
    Lebbe, C.
    Maio, M.
    Pehamberger, H.
    Harmankaya, K.
    Siegel, J.
    Hoos, A.
    Humphrey, R.
    Wolchok, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Robert, Caroline
    Mackiewicz, Andrzej
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Bastholt, Lars
    Hamid, Omid
    Rutkowski, Piotr
    McNeil, Catriona
    Garbe, Claus
    Loquai, Carmen
    Dreno, Brigitte
    Thomas, Luc
    Grob, Jean-Jacques
    Liszkay, Gabriella
    Nyakas, Marta
    Gutzmer, Ralf
    Pikiel, Joanna
    Grange, Florent
    Hoeller, Christoph
    Ferraresi, Virginia
    Smylie, Michael
    Schadendorf, Dirk
    Mortier, Laurent
    Svane, Inge Marie
    Hennicken, Delphine
    Qureshi, Anila
    Maio, Michele
    LANCET ONCOLOGY, 2017, 18 (05): : 611 - 622
  • [7] Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)
    Abdel-Wahab, N.
    Montazari, E. J.
    Spillson, C.
    Amaria, R.
    Glitza, I. C.
    Patel, S.
    Awiwi, M.
    Hassan, A.
    Tahon, N.
    Elsayes, K. M.
    Altan, M.
    Wong, M.
    Mcquade, J.
    Tawbi, H. A.
    Davies, M.
    Yee, C.
    Sharma, P.
    Allison, J.
    Johnson, D.
    Diab, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S923 - S923
  • [8] Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
    Pelster, Meredith
    Gruschkus, Stephen K.
    Bassett, Roland
    Gombos, Dan S.
    Shephard, Michael
    Posada, Liberty
    Glover, Maura
    Diab, Adi
    Hwu, Patrick
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
    Motoo Nomura
    Atsushi Otsuka
    Tomohiro Kondo
    Hiroki Nagai
    Yumi Nonomura
    Yo Kaku
    Shigemi Matsumoto
    Manabu Muto
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 999 - 1004
  • [10] Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
    Nomura, Motoo
    Otsuka, Atsushi
    Kondo, Tomohiro
    Nagai, Hiroki
    Nonomura, Yumi
    Kaku, Yo
    Matsumoto, Shigemi
    Muto, Manabu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) : 999 - 1004
12345